Search results for "Drug carrier"

showing 10 items of 329 documents

Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

2010

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood-brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotei…

Movement disorders/Parkinson’s diseaseDrug CarriersPolymersSurface PropertiesReviewsBrainAlzheimer's diseaseMultiple sclerosisDrug Delivery SystemsMovement disorders/Parkinson's diseaseSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoLiposomesNeuropsychopharmacology.AnimalsHumansNanoparticlesMultiple sclerosiParticle SizeNeuropsychopharmacologyAlzheimer’s diseaseMicellesCentral Nervous System Agents
researchProduct

Dexamethasone dipropionate loaded nanoparticles of α-elastin-g-PLGA for potential treatment of restenosis.

2013

A graft copolymer of α-elastin with poly(lactic-co-glycolic) acid (PLGA) has been synthesized and successfully employed to produce nanoparticles. Exploiting the known biological activity of α-elastin to promote the maintenance of smooth muscle cells (SMCs) contractile phenotype and the antiproliferative effect of glucocorticoids, the aim of this research was to produce drug-loaded nanoparticles suitable for potential treatment of restenosis. In particular, nanoparticles of α-elastin-g-PLGA with a mean size of 200 nm have been produced and loaded with dexamethasone dipropionate (10% w/w), chosen as a model drug that inhibits proliferation of vascular SMCs. These nanoparticles are able to pro…

Myocytes Smooth MusclePharmaceutical ScienceDexamethasoneMuscle Smooth VascularCoronary Restenosischemistry.chemical_compoundPolylactic Acid-Polyglycolic Acid CopolymerDrug DiscoveryMyocyteAnimalsHumansLactic AcidParticle SizeCells CulturedCell ProliferationDrug CarriersbiologyCell growthElastaseBiological activityCell DifferentiationElastinBlotPLGAchemistryBiochemistryBiophysicsbiology.proteinMolecular MedicineNanoparticlesCattleDrug carrierElastinPolyglycolic AcidMolecular pharmaceutics
researchProduct

Photosynthesized silver-polyaminocyclodextrin nanocomposites as promising antibacterial agents with improved activity

2016

Ag nanocomposites were prepared by photoreduction of ammoniacal silver acetate in the presence of poly-{6-[3-(2-(3-aminopropylamino)ethylamino)propylamino]}-(6-deoxy)-β-CD (amCD). The obtained systems were characterized by means of various complementary techniques (UV-vis, FT-IR, TEM, SAED). In particular, FT-IR spectroscopy evidenced a partial oxidative degradation of the polyamine branches of the capping auxiliary, due to the fact that these groups function as a sacrificial reducing agent in the photoinduced formation of the Ag metal core. TEM and SAED micrographs showed that the Ag cores possess a relatively low polydispersity and a significantly crystalline character. The Ag–amCD system…

NanocompositeCyclodextrin Silver nanoparticles Antibacterial activitybiologyReducing agentChemistryGeneral Chemical EngineeringDispersitySupramolecular chemistry02 engineering and technologyGeneral ChemistrySettore CHIM/06 - Chimica Organica010402 general chemistry021001 nanoscience & nanotechnologybiology.organism_classificationAntimicrobialSettore BIO/19 - Microbiologia Generale01 natural sciencesKocuria rhizophila0104 chemical sciencesOrganic chemistry0210 nano-technologyDrug carrierAntibacterial activityNuclear chemistrySettore CHIM/02 - Chimica Fisica
researchProduct

Lipid nanocarriers containing esters prodrugs of Flurbiprofen. Preparation, physical-chemical characterization and biological studies.

2013

In this paper, the preparation, chemical-physical, technological and in vitro characterization of nanostructured lipid carriers (NLC) carrying R-flurbiprofen ester prodrugs, were analyzed for a potential pharmaceutical application. R-flurbiprofen was chosen as a model drug because it has been found to play an effective role in counteracting secretases involved in neurodegenerative diseases, although it does not cross the Blood Brain Barrier (BBB). In this study, two R-flurbiprofen ester prodrugs (ethyl and hexyl) were successfully synthesized and entrapped into non-pegylated and pegylated NLC. The obtained systems showed average diameters in the colloidal size range, negative zeta potential…

Nanostructured Lipid CarriersMaterials scienceMagnetic Resonance SpectroscopyR-Flurbiprofen Ester ProdrugCell SurvivalFlurbiprofenStatic ElectricityBiomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)BioengineeringEsteraseBrain TargetingCell Line TumormedicineZeta potentialHumansGeneral Materials ScienceProdrugsViability assayParticle SizeCytotoxicityCell ShapeDrug CarriersNanostructured Lipid CarrierChromatographyDose-Response Relationship DrugEstersProdrugR-Flurbiprofen Ester ProdrugsLipidsIn vitroNanostructuresCitotoxicity Assays.BiochemistryFlurbiprofenSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryCitotoxicity AssaysDrug Deliverymedicine.drug
researchProduct

Chemical modification of halloysite nanotubes for controlled loading and release.

2020

Clay minerals have been used for medical purposes from ancient times. Among them, the halloysite nanotube, an aluminosilicate of the kaolin group, is an emerging nanomaterial which possesses peculiar chemical characteristics. By means of suitable modifications, such as supramolecular functionalization or covalent modifications, it is possible to obtain novel nanomaterials with tunable properties for several applications. In this context the covalent grafting of suitable organic moieties on the external surface or in the halloysite lumen has been exploited to improve the loading and release of several biologically active molecules. The resulting hybrid nanomaterials have been applied as drug…

NanotubeMaterials scienceTunable properties Controlled drug deliveryHalloysite nanotubeBiomedical EngineeringSupramolecular chemistryNanotechnology02 engineering and technologyengineering.materialChemical characteristic010402 general chemistryYarn Biologically active molecule01 natural sciencesHalloysiteNanomaterialsAluminosilicateKaoliniteGeneral Materials ScienceFunctionalizationGene transferSettore CHIM/02 - Chimica FisicaTargeted drug deliveryCovalent modificationMoleculeGeneral ChemistryGeneral MedicineSettore CHIM/06 - Chimica Organica021001 nanoscience & nanotechnology0104 chemical sciencesNanostructured materialNanotubeSelf-healing hydrogelsengineeringTissue regenerationSurface modificationClay0210 nano-technologyDrug carrierHybrid nanomaterialChemical modificationCovalent graftingJournal of materials chemistry. B
researchProduct

Extracellular Vesicle-Mediated Cell–Cell Communication in the Nervous System: Focus on Neurological Diseases

2019

Extracellular vesicles (EVs), including exosomes, are membranous particles released by cells into the extracellular space. They are involved in cell differentiation, tissue homeostasis, and organ remodelling in virtually all tissues, including the central nervous system (CNS). They are secreted by a range of cell types and via blood reaching other cells whose functioning they can modify because they transport and deliver active molecules, such as proteins of various types and functions, lipids, DNA, and miRNAs. Since they are relatively easy to isolate, exosomes can be characterized, and their composition elucidated and manipulated by bioengineering techniques. Consequently, exosomes appear…

Nervous systemReviewCell CommunicationTheranostic NanomedicineCatalysilcsh:Chemistry0302 clinical medicineCell–cell interactionlcsh:QH301-705.5Tissue homeostasisSpectroscopyDrug Carriers0303 health sciencesnervous systemCell DifferentiationNeurodegenerative DiseasesComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineExtracellular vesicleComputer Science ApplicationsCell biologymedicine.anatomical_structureTheranostics toolExtracellular vesicleextracellular vesiclesneurological diseasesCell signalingCell typecell–cell interactionexosomesBiologyCatalysisInorganic Chemistry03 medical and health sciencesExtracellularmedicineCell-cell interactionHumansPhysical and Theoretical ChemistryMolecular Biology030304 developmental biologytheranostics toolsOrganic ChemistrybiomarkersBiomarkercentral nervous systemMicrovesiclesExosomelcsh:Biology (General)lcsh:QD1-999030217 neurology & neurosurgeryNeurological diseaseInternational Journal of Molecular Sciences
researchProduct

Galactosylated polymeric carriers for liver targeting of sorafenib

2014

In this paper, we describe the preparation of liver-targeted polymeric micelles potentially able to carry sorafenib to hepatocytes for treatment of hepatocarcinoma (HCC), exploiting the presence of carbohydrate receptors, ASGPR. These micelles were prepared starting from a galactosylated polylactide-polyaminoacid conjugate. This latter was obtained by chemical reaction of α,β-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-d,l-aspartamide (PHEA-EDA) with polylactic acid (PLA), and subsequent reaction with lactose, leading to PHEA-EDA-PLA-GAL copolymer. Liver-targeted sorafenib-loaded micelles were obtained in aqueous media at low PHEA-EDA-PLA-GAL copolymer concentration value with nanometer …

NiacinamideSorafenibBiodistributionPolyestersBiological AvailabilityPharmaceutical ScienceAntineoplastic AgentsPharmacologyKidneyMicellechemistry.chemical_compoundPolylactic acidHepatic cell-targeted carriersmedicineZeta potentialAnimalsLungneoplasmsMicellesDrug CarriersActive targetingPhenylurea CompoundsHepatic cell-targeted carrierGalactoseActive targeting; Galactosylation; Hepatic cell-targeted carriers; Polymeric micellesSorafenibEthylenediaminesdigestive system diseasesMice Inbred C57BLLiverBiochemistrychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoGalactosylationDrug deliveryPolymeric micellesFemalePeptidesDrug carrierSpleenmedicine.drugConjugateInternational Journal of Pharmaceutics
researchProduct

Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells

2015

Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC…

NiacinamideSorafenibDrugCell Survivalmedia_common.quotation_subjectnanostructured lipid carriersPharmaceutical ScienceAntineoplastic AgentsPharmacologyHemolysischemistry.chemical_compoundNanostructured lipid carriers Sorafenib Drug release Angiogenesis inhibitor HepatocarcinomamedicineZeta potentialHumansParticle SizeChromatography High Pressure LiquidTriglyceridesdrug releasemedia_commonDrug CarriersPhenylurea CompoundsHep G2 Cellsmedicine.diseaseLipidsControlled releasedigestive system diseasesIn vitroDrug Liberationangiogenesis inhibitorchemistryhepatocarcinomaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsHepatocellular carcinomaTripalmitinDrug deliveryMicroscopy Electron ScanningNanoparticlessorafenibCaprylatesmedicine.drug
researchProduct

Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media

2016

Purpose The aim of this study was to determine the compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media over a period of seven days when stored light protected under refrigerated conditions. Methods DC bead™ (2 ml) (Biocompatibles UK Ltd) of the bead size 70–150 µm ( = DC bead M1) or bead size 100–300 µm were loaded with 75 mg epirubicin powder formulation (Farmorubicin® dissolved in 3 ml water for injection to a concentration of 25 mg/ml) or 76 mg epirubicin injection solution (Epimedac® 2 mg/ml) within 2 h or 6 h, respectively. After removal of the excess solution, the epirubicin-loaded beads were mixed in polypropylene syringes with an equal volume (∼1.5 ml…

Non ionicChemistry PharmaceuticalDrug CompoundingContrast Media01 natural sciences03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug StabilityMedicinePharmacology (medical)Chromatography High Pressure LiquidEpirubicinPolypropyleneDrug CarriersEpirubicin InjectionChromatographyDrug eluting beadsbusiness.industrySyringes010401 analytical chemistryMicrospheres0104 chemical sciencesOncologychemistry030220 oncology & carcinogenesisCompatibility (mechanics)PowdersbusinessEpirubicinmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct